The Minnesota Department of Health reported that as many as 1,000 patients at several Twin Cities clinics were given a steroid product used to treat back pain that is now linked to a widening national outbreak of a rare kind of meningitis. Meningitis is an inflammation of the lining of the brain and spinal cord which can lead to severe complications. Click here for more on this story.
Pradaxa is a prescription blood thinner used to prevent strokes and blood clots in people with atrial fibrillation not caused by a heart valve problem. Unlike a similar drug on the market, Coumadin, there are serious bleeding and cardiac risks with Pradaxa because there is no reversal agent to counteract Pradaxa’s anticoagulation effects.
The United States Judicial Panel on Multidistrict Litigation (JPML) recently consolidated all federal court Pradaxa drug injury lawsuits into the following case: IN RE: PRADAXA (DABIGATRAN ETEXILATE) PRODUCTS LIABILITY LITIGATION, MDL No. 2385.
The Medtronic Infuse Bone Graft System uses a liquid bone protein to encourage bone growth in spinal fusion surgery. However, its “off-label” non-FDA approved use in certain types of fusion surgery may lead to serious adverse effects.
In a recent California case, the court determined that the plaintiff’s injury claims from the Infuse System were not preempted by federal law under the US Supreme Court’s decision in Reigel v. Medtronic, Inc (552 U.S. 312) because Medtronic promoted the Infuse product for off label uses.